诺和锐30与诺和灵30R治疗2型糖尿病的临床疗效比较

目的比较诺和锐30与诺和灵30R治疗2型糖尿病（T2DM）的疗效及不良反应。方法60例T2DM患者随机分为诺和锐30组和诺和灵30R组，分别给予诺和锐30或诺和灵30R2次，d治疗，治疗3个月后，观察血糖控制情况及低血糖发生情况。结果①治疗后两组患者空腹血糖（FPG）、餐后2h血糖（2hPBG）、糖化血红蛋白（HbAlc）均较治疗前明显下降（P〈0．01），但诺和锐30组2hFPG、HbAlc下降更明显（P〈0．05）。②在控制血糖更佳的同时，诺和锐30所需剂量较诺和灵30R减少（P〈0．05）。③诺和锐30组低血糖发生率显著低于诺和灵30R组（P〈0．05）。结论诺和锐30能更好地降低T2DM血糖水平，减少低血糖反应，减少胰岛素剂量。

Comparative Study on Efficacy of Novomix 30 and Novolin 30R for Treatment of Type 2 Diabetes Mellitus

Objective To compare the efficacy and adverse reaction of Novomix 30 and Novolin 30R in patients with type 2 diabetes mellitus. Methods Sixty patients with type 2 diabetes mellitus were divided into two groups at random, they were given Novomix 30 and Novolin 30R twice daily for 3 months, and blood glucose and hypoglycemia were observed. Results （1） FPG,2hPBG, HbAlc decreased significantly in the two groups after treatment than that before （P 〈 0.01 ）. In Novomix 30 group 2hPBG, HbAlc control was superior to Novolin 3OR. （2） Novomix30 group in controlling blood sugar was better at the same time, was needed to all doses reduction than Novolin 30R （ P 〈 0.05 ）. （3） The incidence of hypoglycemia was lower in Novomix 30 group （ P 〈 0.05 ）. Conclusion For patients with type 2 diabetes mellitus, Novomix 30 can better reduce blood glucose levels and the incidence of hypoglycemia, and can reduce the dosage of insulin.